MilliporeSigma
  • BP1083
All Photos(1)

BP1083

Isoniazid

British Pharmacopoeia (BP) Reference Standard

Synonym(s):
4-Pyridinecarboxylic acid hydrazide, INH, Isonicotinic acid hydrazide, Isonicotinic hydrazide
Empirical Formula (Hill Notation):
C6H7N3O
CAS Number:
Molecular Weight:
137.14
Beilstein:
119374
MDL number:

grade

pharmaceutical primary standard

manufacturer/tradename

BP

mp

171-173 °C (lit.)

format

neat

storage temp.

2-8°C

SMILES string

NNC(=O)c1ccncc1

InChI

1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

InChI key

QRXWMOHMRWLFEY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

1 of 4

This Item
N7035PHR16351349706
Isoniazid British Pharmacopoeia (BP) Reference Standard

BP1083

Isoniazid

Nizatidine analytical standard

Supelco

N7035

Nizatidine

Oxcarbazepine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1635

Oxcarbazepine

Isoniazid United States Pharmacopeia (USP) Reference Standard

USP

1349706

Isoniazid

grade

pharmaceutical primary standard

grade

analytical standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

manufacturer/tradename

BP

manufacturer/tradename

-

manufacturer/tradename

-

manufacturer/tradename

USP

format

neat

format

neat

format

neat

format

neat

mp

171-173 °C (lit.)

mp

-

mp

-

mp

171-173 °C (lit.)

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

storage temp.

2-8°C

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. Selectively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations.

Packaging

Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

Other Notes

Sales restrictions may apply.

Certificate of Analysis

Enter Lot Number to search for Certificate of Analysis (COA).

Certificate of Origin

Enter Lot Number to search for Certificate of Origin (COO).

More Documents

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service